D. E. Shaw & Co. Inc. Acquires 40,001 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)

D. E. Shaw & Co. Inc. lifted its holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 54.9% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 112,841 shares of the company’s stock after purchasing an additional 40,001 shares during the period. D. E. Shaw & Co. Inc. owned about 0.15% of Nurix Therapeutics worth $2,126,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. JPMorgan Chase & Co. lifted its stake in shares of Nurix Therapeutics by 85.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 68,148 shares of the company’s stock worth $1,531,000 after purchasing an additional 31,352 shares during the period. Jump Financial LLC bought a new position in shares of Nurix Therapeutics in the 4th quarter worth approximately $1,406,000. Barclays PLC lifted its stake in shares of Nurix Therapeutics by 77.9% in the 3rd quarter. Barclays PLC now owns 128,344 shares of the company’s stock worth $2,884,000 after purchasing an additional 56,190 shares during the period. Sumitomo Mitsui Trust Group Inc. lifted its stake in shares of Nurix Therapeutics by 42.7% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 789,222 shares of the company’s stock worth $14,869,000 after purchasing an additional 235,971 shares during the period. Finally, Affinity Asset Advisors LLC lifted its stake in shares of Nurix Therapeutics by 9.3% in the 4th quarter. Affinity Asset Advisors LLC now owns 940,083 shares of the company’s stock worth $17,711,000 after purchasing an additional 79,684 shares during the period.

Nurix Therapeutics Stock Performance

NRIX stock opened at $10.14 on Wednesday. The firm has a fifty day moving average price of $10.91 and a 200 day moving average price of $16.65. Nurix Therapeutics, Inc. has a fifty-two week low of $8.18 and a fifty-two week high of $29.56. The firm has a market cap of $773.03 million, a PE ratio of -3.51 and a beta of 2.23.

Nurix Therapeutics (NASDAQ:NRIX) last posted its earnings results on Tuesday, April 8th. The company reported ($0.67) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.05. Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%. The firm had revenue of $18.45 million during the quarter, compared to analyst estimates of $12.78 million. During the same period last year, the firm posted ($0.76) earnings per share. On average, equities analysts predict that Nurix Therapeutics, Inc. will post -2.99 EPS for the current year.

Analyst Ratings Changes

NRIX has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. decreased their target price on shares of Nurix Therapeutics from $31.00 to $30.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 29th. Wells Fargo & Company decreased their target price on shares of Nurix Therapeutics from $32.00 to $25.00 and set an “overweight” rating on the stock in a research note on Wednesday, April 9th. Morgan Stanley raised their target price on shares of Nurix Therapeutics from $16.00 to $17.00 and gave the stock an “equal weight” rating in a research note on Monday, February 3rd. Royal Bank of Canada raised their target price on shares of Nurix Therapeutics from $26.00 to $27.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 29th. Finally, Stephens restated an “overweight” rating and set a $31.00 target price on shares of Nurix Therapeutics in a research note on Tuesday, January 21st. Three investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $30.44.

Insider Activity at Nurix Therapeutics

In related news, CFO Houte Hans Van sold 5,825 shares of the firm’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $14.49, for a total value of $84,404.25. Following the completion of the transaction, the chief financial officer now directly owns 33,724 shares of the company’s stock, valued at approximately $488,660.76. This trade represents a 14.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Gwenn Hansen sold 3,377 shares of Nurix Therapeutics stock in a transaction on Wednesday, April 30th. The stock was sold at an average price of $11.50, for a total transaction of $38,835.50. Following the transaction, the insider now directly owns 61,516 shares of the company’s stock, valued at $707,434. The trade was a 5.20% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 17,838 shares of company stock valued at $221,500. 7.40% of the stock is owned by corporate insiders.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.